Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
FinWise Bancorp's Board of Directors authorized an amendment to its existing share repurchase program, adding 600,000 shares to the authorization. This increases the total aggregate amount the company may purchase to 1,285,000 shares of common stock, reflecting management's confidence in the company's long-term trajectory and strong capital position.
Ligand Pharmaceuticals Insider Jason Aryeh Sells $957K of Stock
Jason Aryeh sold 2,990 shares of Ligand Pharmaceuticals Inc at $319.99 to $320.20 a share (average $320.05) in 5 transactions, worth $957K in total on Nov 10, 2026. Shares held after the trade: 105,476 (-0.5%).
APi Group Insider James E. Lillie Sells $14.9M of Stock
James E. Lillie sold 349,999 shares of APi Group Corp at $42.45 a share, worth $14.9M in total on Nov 9, 2026. Shares held after the trade: 8,664,852 (-3.2%).
Xometry CTO Vaidyanathan Raghavan Sells $600K of Stock
Vaidyanathan Raghavan, CTO, sold 5,000 shares of Xometry, Inc. at $120.00 a share, worth $600K in total on Nov 10, 2026. Shares held after the trade: 128,911 (-3.7%).
TMC the metals company Inc. reported a significant increase in exploration and evaluation expenses to $92.9 million for the nine months ended September 30, 2026, compared to $29.6 million in the prior year. The company recorded a net operating loss of $138.7 million for the same period, while its cash position decreased to $79.3 million from $117.6 million at year-end 2025.
Jesse Weaver, CFO, bought 9,000 shares of Holley Inc. at $2.53 a share, worth $22.8K in total on Nov 10, 2026. Shares held after the trade: 670,695 (+1.4%).
Pinterest Insider Benjamin Silbermann Sells $1.78M of Stock
Benjamin Silbermann sold 93,750 shares of Pinterest, Inc. at $18.90 to $19.00 a share (average $18.95) in 2 transactions, worth $1.78M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 0 (-100.0%).
Boot Barn Holdings CFO & Secretary James M. Watkins Buys $271K of Stock
James M. Watkins, CFO & Secretary, bought 2,000 shares of Boot Barn Holdings, Inc. at $135.37 a share, worth $271K in total on Nov 12, 2026. Shares held after the trade: 27,831 (+7.7%).
First Eagle Private Credit Fund reported total non-controlled/non-affiliated investments at a fair value of $526.5 million as of September 30, 2026, a decrease from $567.3 million at year-end 2025. The fund maintained $38.5 million in cash and cash equivalents and reported 12,844,156 Class I shares outstanding as of November 12, 2026.
Marblegate Capital Corp reported a net loss of $9.8 million for the nine months ended September 30, 2026, compared to a $52.3 million loss in the prior year period. While total revenue grew to $47.2 million driven by fleet operations, the company faced increased operating expenses and net losses on loans held for investment.
For the nine months ended September 30, 2026, Andalusian Credit Company, LLC reported total investment income of $30.5 million and net investment income of $13.2 million. Total net assets grew to $417.5 million, driven by $71.1 million in share issuance proceeds, while the net asset value per share increased slightly to $15.33.
Greenland Mines Equity Investment in Battery Mineral Resources Corp.
Greenland Mines Ltd entered into a subscription agreement to purchase 7,000,000 shares of Battery Mineral Resources Corp. (BMR) for C$1.4 million. Additionally, the company exercised an option to acquire 25,168,669 shares of AnorTech Inc. for C$7.55 million, paid via the issuance of 1,133,268 newly issued shares of Greenland Mines common stock.
InspireMD reported third quarter 2026 financial results, highlighted by total revenue of $2.2 million, a 9% increase year-over-year driven by international performance. During the quarter, the company received FDA approval for its CGuard Prime carotid stent system for TCAR procedures, which is expected to double its U.S. addressable market with a commercial launch planned for Q4 2026.
Term
Q3 2026
“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-g”
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.
Astec Industries Divestiture to Komatsu America Corp. for $75M
Astec Industries has entered into a definitive agreement to sell its road construction equipment business, including the Roadtec and Carlson brands, to Komatsu America Corp. for $75 million in cash. The divestiture of the loss-making business is expected to improve Astec's adjusted EBITDA margin by approximately 200 basis points and sharpen focus on its core higher-margin product portfolio.
Value
$75M
Counterparty
Komatsu America Corp.
“The Roadtec Business has been an important part of Astec, and I want to thank our Roadtec employees for their dedication and contributions and our customers for their partnership and loyalty over the years. We are pleased to have entered into this agreement with Komatsu, a strategic buyer who values the Roadtec brand, technology, engineering expertise and team members. This transaction is consistent with our strategy to sharpen our portfolio focus, drive sustainable margin expansion and allocate capital toward our core businesses and long-term growth opportunities.”
Jaco van der Merwe, Astec President and Chief Executive Officer
Bio Green Med Solution, Inc. is undergoing a significant business combination with Future NRG Sdn. Bhd. (FNRG), which will result in FNRG shareholders owning over 99% of the combined company. The company recently deconsolidated its former subsidiary, Cyclacel Limited, following a creditors voluntary liquidation and has pivoted its business focus through various asset sales and exchange agreements.
Beta Bionics CFO Stephen Feider Sells $12.6K of Stock
Stephen Feider, CFO, sold 744 shares of Beta Bionics, Inc. at $17.00 a share, worth $12.6K in total on Nov 9, 2026. Shares held after the trade: 159,378 (-0.5%).
Hippo Holdings CEO Richard McCathron Sells $176K of Stock
Richard McCathron, CEO, sold 5,000 shares of Hippo Holdings Inc. at $35.25 a share, worth $176K in total on Nov 9, 2026. Shares held after the trade: 557,132 (-0.9%).
Ipek Erdogan-Trinkaus, Chief Commercial Officer, sold 3,500 shares of Eton Pharmaceuticals, Inc. at $67.18 to $67.88 a share (average $67.41) in 2 transactions, worth $236K in total on Nov 10, 2026. Shares held after the trade: 4,081 (-22.1%).
Aeluma reported Q1 fiscal 2027 financial results with revenue of $0.6M and a net loss of $3.8M. The company highlighted a new purchase agreement with Aixtron for MOCVD manufacturing expansion and ongoing negotiations for $30M in CHIPS Act funding.
Term
Q1 2027
“The current U.S. AI infrastructure buildout continues to progress and is expected to reach an aggregate investment of $10.3 trillion in 2032. The opportunities for photonics are vast, spanning scale-up and scale-out AI architectures in data centers.”
Jonathan Klamkin, Ph.D., Founder and CEO
“As we progress through fiscal 2027, we remain focused on technology and product development for AI Datacom opportunities. Aeluma’s high-speed photodetectors and quantum dot lasers continue to attract customer attention.”
Sutro Biopharma reported third quarter 2026 financial results, highlighting a cash position of $142.2 million which is expected to fund operations into the first half of 2028. The company advanced its clinical pipeline with the first patient dosed in the STRO-006 Phase 1 study and reported progress on its STRO-004 and STRO-227 ADC programs.
Term
3 months
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027.”
Jane Chung, Chief Executive Officer of Sutro
“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”
Live Oak Bancshares, Inc. closed an underwritten public offering of 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Fixed Rate Series B Non-Cumulative Perpetual Preferred Stock. The offering raised approximately $96.25 million in net proceeds after underwriting discounts and expenses, with the shares carrying a liquidation preference of $25 per depositary share.
Stark Novus Financial Inc. held its 2026 Annual Meeting of Stockholders on November 9, 2026. Shareholders elected Paul Burkett and Alexandre Zyngier as Class II directors for three-year terms and ratified BDO USA, P.C. as the company's independent accounting firm for the 2026 fiscal year.
PIMCO Capital Solutions BDC Corp. reported that non-qualifying assets represented 1.7% of total net assets as of September 30, 2026, down from 3.2% at year-end 2025. The company also disclosed a significant affiliated investment in Voyatek with a fair value of approximately $23.1 million and noted that its credit facility's unused commitment fee expired in June 2026.
Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”
Esther Rajavelu, President and Chief Executive Officer
Battalion Oil Corp reported total operating revenues of $45.6 million for the quarter ended September 30, 2026, with a net income from operations of $5.0 million. However, the company faced a significant net loss on derivative contracts of $44.8 million during the quarter, compared to a gain in the prior year period.
Starling Oncology, Inc. furnished an updated investor presentation as Exhibit 99.1 to be used in upcoming meetings with investors. This filing is an amendment (Form 8-K/A) that supersedes a previous version of the presentation filed earlier the same day.
Synchrony Card Issuance Trust Debt Financing Update with BofA Securities, Inc.
Synchrony Card Funding, LLC and Synchrony Bank entered into an underwriting agreement with BofA Securities, Barclays Capital, and Wells Fargo Securities for the issuance of Class A(2026-3) Notes. The notes will be issued by the Synchrony Card Issuance Trust under an existing master indenture and a new terms document. This filing establishes the legal and underwriting framework for the upcoming debt issuance.
Silexion Therapeutics Corp is a development-stage biotechnology company focused on its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. As of November 12, 2026, the company reported 649,528 ordinary shares outstanding and continues to operate as an emerging growth company with no product revenue to date.
Aramark filed an amendment to a previous 8-K to report that director Antony F. Spring has been appointed to the Compensation and Human Resources and Finance and Technology committees of the Board. Mr. Spring was originally elected to the Board on August 4, 2026, but committee assignments had not been determined at that time.